Mark Gurney (Tetra Therapeutics)
Ahead of crucial PhII readout, Shionogi lines up an option to buy out biotech partner and its non-amyloid Alzheimer's drug
With the make-or-break results that will prove little Tetra right — or wrong — about its Alzheimer’s drug just around the corner, partner Shionogi is putting itself in a position to act quickly should the Phase II trial come back positive.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.